Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending December 20, 2002. The report primarily details changes in directors' interests in company shares and a specific share repurchase transaction executed on December 19, 2002.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data points disclosed relate to specific share transactions:
- Share Repurchase Price: 1,127.45p per share.
- ADR Fund Average Price: $36.10.
Material Changes
The filing reports two material corporate actions:
- Share Repurchase: On December 19, 2002, the company purchased 880,000 ordinary shares for cancellation under authority granted at the May 20, 2002 Annual General Meeting.
- Directors' Interests: The GlaxoSmithKline US Retirement Savings Plan increased its holdings of Ordinary Share ADRs from 18,283,037 to 18,284,894 due to fund movements on December 19, 2002. Directors Dr. J.P. Garnier and Mr. J.D. Coombe hold interests in these shares as beneficiaries of the plan.
Guidance, Outlook, and Risks
The filing text does not provide management commentary, future guidance, outlook, risk factors, contingencies, or unusual items beyond the disclosed share transactions.
Key Facts for Investor Verification
- Verify the total number of shares repurchased by GSK since the May 2002 authorization to assess the remaining buyback capacity.
- Confirm the current market price of GSK shares relative to the 1,127.45p repurchase price to evaluate the efficiency of the buyback.
- Review the full composition of the US Retirement Savings Plan to understand the extent of director exposure to company stock.